Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > How could Mackie have sold this to their clients

<< Previous

Bullboard Posts

Next >>

Comment by ANALIAS00on Feb 02, 2021 2:37pm

90 Views

Post# 32448806

RE:How could Mackie have sold this to their clients

:o) So funny ...well .... You know what I mean !

SPCEO1 wrote: if they really only beliesve there is a 10% chance of success in NASH?

None of this adds up. The foolishness of it all is hard to take on all fronts.

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals